Samuel Urrutia
Assistant Professor of Medicine
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (19)
Year:
2026
Year:
2025
TP53 mutations are found in 10% to 15% of myeloid neoplasms and are one of its most important prognostic factors. Emerging data show that TP53 mutational allele status is a key determinant of clinical outcomes, with multihit TP53 mutant myeloid neoplasms having a very poor prognosis. Significant differences exist among the methods used in clinical and research settings to assess TP53 mutational status, leading to variability in reported patient characteristics, response to therapy, and survival. Indeed, differences in the criteria used to define TP53 mutational states among professional societies and in landmark research studies have led to confusion, suboptimal clinical testing, and variability in therapy recommendations. We review the methods used to assess for TP53 mutational allele status and provide recommendations, based on clinically available testing, for the accurate evaluation of TP53 gene mutations in myeloid neoplasms. Hotspot mutations represent ∼35% of all TP53 missense mutations in myeloid neoplasms. There is evidence that these hotspot mutations may have dominant-negative or gain-of-function properties. Here, we review this evidence and discuss the potential impact of TP53 mutation identity on patient outcomes and clinical management.
Year:
2025
Background: Acute promyelocytic leukemia (APL) is prevalent in Latin America and carries a high risk of early-onset complications. However, outcome data for APL in this region are limited. Since 2020, Chile has adopted all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) as the standard therapy for APL. In this real-world study, we describe the characteristics, survival outcomes, and causes of death (COD) for adult APL patients in Chile. Methods: This multicenter, retrospective study analyzed data from 174 adult patients diagnosed with APL across 16 public institutions in Chile between 2013 and 2024. Causes of death were obtained from electronic medical record reviews and death certificates. Time-to-event analyses were conducted using the log-rank test and Kaplan-Meier survival estimates. Results: Of the 174 patients, 90 (52%) were male. The median age at diagnosis was 41 years (IQR: 32–56). Patient distribution by region was as follows: Metropolitan (56%), Biobío (14%), Valparaíso (8.6%), and Antofagasta (6.9%). The incidence of APL was higher in the northern region of Antofagasta at 2 cases per 100,000 inhabitants, compared to a range of 0.9–1.2 per 100,000 in other regions. The t(15;17) translocation was confirmed in 149 patients (86%). Trisomy 8 was found in 21 patients (12%), and a complex karyotype was present in 16 patients (9.2%). The median overall survival (mOS) for the cohort was 2.55 years (IQR: 0.8–5.6). In the multivariate analysis, sex, year of diagnosis, and other cytogenetic abnormalities were not statistically significant predictors of survival (p>0.05). At the time of analysis, 39 patients (22%) were deceased. Of these deaths, 29 (74%) occurred within the first 30 days (early mortality). The proportion of early deaths was 78% (22 of 28 total deaths) prior to the adoption of the ATRA/ATO regimen, compared to 63% (7 of 11 total deaths) after its adoption. The most common COD were bleeding (n=14, 48%), respiratory failure (n=4, 14%), and sepsis (n=2, 6.9%). Conclusion: In this cohort, mortality was primarily driven by early complications, particularly bleeding and respiratory failure. The higher incidence of APL in the Antofagasta region warrants further investigation. Although the adoption of ATRA/ATO lowered overall mortality, early deaths from bleeding remains high. Early recognition of and intervention for coagulopathy are critical to improving survival outcomes in this population
Year:
2025
Year:
2025
Purpose: Hypomethylating agents (HMA) combined with venetoclax are an emerging therapeutic strategy for higher-risk myelodysplastic syndromes (HR-MDS). The cytogenetic and molecular factors associated with outcomes with this combination for HR-MDS are incompletely understood. Experimental Design: We pooled patient data from 3 prospective trials evaluating HMA–venetoclax in HR-MDS to study associations between cytogenetic and molecular factors and overall response rate (ORR), overall survival (OS), and event-free survival (EFS). The Kaplan–Meier method was used to estimate time-to-event endpoints. Univariate and multivariate analyses using logistic regression (for ORR) or the Cox proportional hazards model (for OS and EFS) were used to identify associations between clinical, cytogenetic, and molecular factors and outcomes. Results: A total of 80 patients (52 HMA-naïve, 28 HMA-failure) were included. ORR was 90% in HMA-naïve and 57% in HMA-failure. Median OS was 28.2 and 8.3 months in HMA-naïve and HMA-failure, respectively. Median EFS was 17.9 and 5.5 months in HMA-naïve and HMA-failure, respectively. In addition, 24/52 (46%) of the HMA-naïve and 3/28 (11%) of the HMA-failure patients proceeded to allogeneic stem cell transplantation (SCT). Factors associated with inferior outcomes were prior HMA failure, complex cytogenetics, trisomy 8, TP53 mutations, and RAS pathway mutations. Mutations in RNA splicing, DNA methylation, and ASXL1 appeared favorable. Blast percentage was not predictive of outcomes. Conclusions: Knowledge of cytogenetic and molecular alterations may help identify which patients with HR-MDS benefit the most from venetoclax.
Year:
2024
Therapy-related myeloid neoplasms (t-MNs) arise after exposure to cytotoxic therapies and are associated with high-risk genetic features and poor outcomes. We analyzed a cohort of patients with therapy-related chronic myelomonocytic leukemia (tCMML; n = 71) and compared its features to that of de novo CMML (dnCMML; n = 461). Median time from cytotoxic therapy to tCMML diagnosis was 6.5 years. Compared with dnCMML, chromosome 7 abnormalities (4% vs. 13%; P = .005), but not complex karyotype (3% vs. 7%; P = .15), were more frequent in tCMML. tCMML was characterized by higher TP53 mutation frequency (4% vs. 12%; P = .04) and lower NRAS (6% vs 22%, P =0.007) and CBL (4% vs 12%, P =0.04) mutation frequency. Prior therapy with antimetabolites (OR, 1.22 [95% CI, 1.05-1.42]; P = .01) and mitotic inhibitors (OR, 1.24 [95% CI, 1.06-1.44]; P = .009) was associated with NF1 and SETBP1 mutations while prior mitotic inhibitor therapy was associated with lower TET2 mutation frequency (OR, 0.71 [95% CI, 0.55-0.92]; P = .01). Although no differences in median overall survival (OS) were observed among tCMML and dnCMML (34.7 months vs 35.9 months, P = .26), multivariate analysis for OS revealed that prior chemotherapy was associated with increased risk of death (HR 1.76 [95% CI, 1.07-2.89]; P = .026). Compared to a cohort of therapy-related myelodysplastic syndrome, tCMML had lower TP53 mutation frequency (12% vs 44.4%, P <.001) and less unfavorable outcomes. In summary, tCMML does not exhibit the high-risk features and poor outcomes of t-MNs. -
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (24)
Gautam Borthakur
The University of Texas MD Anderson Cancer Center
Hagop Kantarjian
-
Hussein A. Abbas
The University of Texas MD Anderson Cancer Center
Georgina Gener-Ricos
Assitant Professor
Institut Català d'Oncologia
Alex Bataller Torralba
The University of Texas MD Anderson Cancer Center
Ghayas C. Issa
Assistant Professor
The University of Texas MD Anderson Cancer Center
Guillermo Montalban-Bravo
Assistant Professor
The University of Texas MD Anderson Cancer Center
Rashmi Kanagal Shamanna
The University of Texas MD Anderson Cancer Center
Sanam Loghavi
The University of Texas MD Anderson Cancer Center
Daniel C. Link
Washington University School of Medicine
Koji Sasaki
Chair and Professor
The University of Texas MD Anderson Cancer Center
Farhad Ravandi
Professor of Medicine, Chief Section of AML
The University of Texas MD Anderson Cancer Center
Elizabeth Griffiths
Professor
Roswell Park Comprehensive Cancer Center
Ziyi Li
Assistant Professor
The University of Texas MD Anderson Cancer Center
Amer M. Zeidan
Yale University School of Medicine
Nicholas J. Short
-
Wei-Ying Jen
National Cancer Institute
Yesid Alvarado Valero
Associate Professor
The University of Texas MD Anderson Cancer Center
Tapan M. Kadia
The University of Texas MD Anderson Cancer Center
Elias J. Jabbour
Professor
The University of Texas MD Anderson Cancer Center
Courtney D. DiNardo
University of Pennsylvania
Guillermo Garcia-Manero
The University of Texas MD Anderson Cancer Center
Sangeetha Venugopal
Assistant professor
Sylvester Comprehensive Cancer Center
Naval G. Daver
Professor of Medicine
The University of Texas MD Anderson Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.